| 2019-MITT-68665 | |
| Researchers at Purdue University have developed a novel addition to traditional vaccines which includes painless intranasal delivery of an Autophagy Inducing Peptide (AIP) for directly inhibiting the root cause of the tuberculosis—Mtb. Mtb is a leading cause of death worldwide, leading to 1.5 million fatalities annually. Those highly susceptible to (Mtb), expressly at-risk seniors and children, are not completely protected by currently available preventative Bacillus Calmette Guérin vaccines. Purdue researchers have created a vaccine to allow the body's immune system to fight Mtb antigens using a mycobacterial antigen-85B, for targeting Mtb, with autophagy-inducing peptide, C5 from CFP10 proteins that contribute to virulence of Mtb, that can be expressed by a bovine adenoviral vector (BAd85C5) or a human adenoviral vector (HAd85C5). In testing in mice, the new vaccines were administered along with an intranasal aerosol-based booster. Robust effector (TEM) and central memory (TCM) T cell response was achieved with the Bad85C5 vaccine, and IL-12 expression was observed to monitor effectiveness of C5, validating an enhanced immune response in mice. Advantages: -Improves Pediatric Care -Less Invasive -Enhanced T Cell Response Potential Applications: -Tuberculosis Vaccine -Vaccine approach for other infectious diseases -Cancer Treatments -Life Science Research Technology Validation: The new TB vaccine strategy was tested in mice conferring significant protection from an intranasal Mtb challenge. |
|
|
|
|
Mar 12, 2021
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |